New research published in Basic & Clinical Pharmacology & Toxicology by scientists at the University of Toronto found that the non-psychoactive cannabinoids cannabidiol (CBD) and cannabigerol (CBG) ...

Xenon Pharmaceuticals Inc. Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026. Five additional Phase 3 azetu ...

LISLE, IL, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- OWP Pharmaceuticals today announced commercial product ...

The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is propelled by a combination of unprecedented financial investment, a rich ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough ...

People with a genetic predisposition for Alzheimer's disease may have an increased risk of epilepsy and people with a certain type of epilepsy may have an increased risk of developing Alzheimer's ...

-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- The PMA-S is ...

After experiencing a seizure, children were seen by a neurology epilepsy specialist a median of 6 days after referral to the first-seizure clinic. HealthDay News — Children referred to a first seizure ...

-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...

A seizure (SEE-zhur) is unusual electrical activity in the brain. Normally, electrical activity in the brain involves neurons (nerve cells) in different areas sending signals at different times.